[The effect of ranitidine and famotidine on the intragastric pH profile of healthy subjects. Randomized cross-over trial with ranitidine effervescent tablets (300 mg) versus famotidine film tablets (40 mg) ].
Influence of Ranitidine and Famotidine on the Intragastric pH-profile in Healthy Volunteers/Randomised cross-over study of ranitidine effervescent tablets (300 mg) versus famotidine film coated tablets (40 mg). A controlled cross-over trial was carried out to compare the duration of time until the onset of action and its intensity following administration of ranitidine (R, Sostril, CAS 76824-35-6) effervescent tablets (300 mg) and famotidine (F, CAS 76824-35-6) film coated tablets (40 mg). Twelve volunteers (4 female, 8 male) participated in the study. The efficacy of the test medications was assessed by pH-metry during 12 h. The evaluation of the measurements showed that a pH-value 3.5 was reached 100 s after administration of R and 3,392 s (56.5 min) after F (p < 0.01). The median pH-values were significantly higher after R during the first 2 h. The AUC-values (area under the curve; pH-time) for 1, 2 and 4 h were calculated by the trapezoid rule. The intake of R resulted in significantly higher areas than that of F. After reaching the pH-value of 3.5 this value remained stable during the complete period of measurement (R = 12 h, F = 11 h). The faster onset of pH-value elevation could correspond clinically with a faster onset of pain relief.
Löser
C
C
Klinikum der Christian-Albrechts-Universität, I. Medizinische Klinik, Kiel.
Burlage
M
M
Fölsch
U R
UR
D000328:Adult; D015738:Famotidine / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D005744:Gastric Acid / Q000737:chemistry*; D006801:Humans; D008297:Male; D011899:Ranitidine / Q000008:administration & dosage / Q000494:pharmacology*; D013607:Tablets; D013608:Tablets, Enteric-Coated
D013607:Tablets; D013608:Tablets, Enteric-Coated; D015738:Famotidine; D011899:Ranitidine
Einfluss von Ranitidin und Famotidin auf das intragastrale pH-Profil von gesunden Probanden. Randomisierte Cross-over-Prüfung mit Ranitidin-Brausetabletten (300 mg) versus Famotidin-Filmtabletten (40 mg).